The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need multiple drugs. The use of these combination antihypertensives as first-line treatment may reduce time to reach hypertension goals and increase compliance by reducing pill burden.

These approvals were based on several clinical trials in which both products demonstrated efficacy and tolerability in patients with mild-to-severe hypertension.

For more information visit www.diovanhct.com or www.exforge.com.